Summary
To assess whether pretreatment with intracoronary nifedipine protects the myocardium against acute ischemia induced by coronary occlusion, 18 patients were studied during coronary angioplasty of the left anterior coronary artery. After a control occlusion of 60 seconds, 0.1 mg nifedipine was injected and occlusion was repeated for 60 seconds. Before and during the occlusion period, pulmonary capillary pressure was measured and the intracoronary epicardial ECG was recorded. After intracoronary administration of nifedipine, the onset of the rise in diastolic filling pressure was delayed from 23 to 38 seconds (p<0.01) and the changes at 60 seconds of occlusion were reduced from 14 to 11 mmHg (p<0.05). Nifedipine delayed the appearance of ischemic ST-segment elevation in the intracoronary ECG from 11 to 21 seconds (p<0.01) and diminished the changes at 60 seconds of occlusion from 1.8 to 1.2 mV (p<0.05). These findings suggest that pretreatment with intracoronary nifedipine protects the myocardium against some of the mechanical and electrocardiographic consequences of regional ischemia during acute coronary occlusion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Henry PD, Shuchleib R, Borda LJ, et al..Effects of nifedipine on myocardial perfusion and ischemic injury in dogs.Circ Res 1978;43:372–413.
Clark RE, Christlieb IY, Henry PD, et al. Nifedipine: A myocardial protective agent.Am J Cardiol 1979;44:825–831.
Nayler WG, Ferrari R, Williams A. Protective effects of pretreatment with verapamil, nifedipine, and propranolol on mitochondrial function in the ischemic and reperfused myocardium.Am J Cardiol 1980;46:242–248.
Fleckenstein A, Fleckenstein-Grün G. Cardiovascular protection by Ca antagonists.Eur Heart J 1980;1 (Suppl B):15–21.
Opie LH, Calcium, calcium ions, and cardiovascular disease. In: Opie LH, ed.Calcium antagonists and cardiovascular disease. New York: Raven Press, 1984:1–8.
Serruys PW, van den Brand M, Brower RW, Hugenholtz PG. Regional cardioplegia and cardioprotection during transluminal angioplasty: Which role for nifedipine?Eur Heart J 1983;4(Suppl C):115–121.
Hanet C, Rousseau MF, Vincent MF, et al. Myocardial protection by intracoronary nicardipine administration during percutaneous transluminal coronary angioplasty.Am. J. Cardiol 1987;59:1035–1040.
Amende I, Herrmann G, Simon R, Lichtlen PR. Effect of nisoldipine and nitroglycerin on myocardial ischemia and dysfunction during coronary angioplasty. In: Hugenholtz PG, Meyer J, eds.Nisoldipine 1987. Berlin: Springer-Verlag, 1987:238–243.
Werner GS, Schmidt M, Klein HH, et al. Verapamil as a potent cardioprotective agent for coronary angioplasty: First clinical experience.J Am Coll Cardiol 1989;13:154A.
Friedman PL, Shook TL, Kirshenbaum JM, et al. Value of the intracoronary electrocardiogram to monitor myocardial ischemia during percutaneous transluminal coronary angioplasty.Circulation 1986;74:330–339.
Sharma B, Seth L, Bisset JK et al. Significance of percutaneous intracoronary epicardial electrocardiography during coronary angioplasty.J Am Coll Cardiol 1986;7:127A.
Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects.J Am Coll Cardiol 1985;5:587–592.
Cohen M, Sherman W, Rentrop KP, Gorlin R. Determinants of collateral filling observed during sudden controlled coronary artery occlusion in human subjects.J Am Coll Cardiol 1989;13:297–303.
Serruys PW, Wijns W, van den Brand M, et al. Left ventricular performance, regional blood flow, wall motion, and lactate metabolism during transluminal angioplasty.Circulation 1984;70:25–36.
Wijns W, Serruys PW, Slager CJ, et al. Effect of coronary occlusion during percutaneous transluminal angioplasty in humans on left ventricular chamber stiffness and regional diastolic pressure-radius relations.J Am Coll Cardiol 1986;7:455–463.
Connolly OC, Kirklin JW, Wood EH. The relationship between pulmonary artery wedge pressure and left atrial pressure in man.Circ Res 1954;2:434–440.
Amende I, Simon R, Hood WP Jr, et al. Intracoronary nifedipine in human beings: Magnitude and time course of changes in left ventricular contraction/relaxation and coronary sinus blood flow.J Am Coll Cardiol 1983;2:1141–1145.
Erbel R, Schreiner G, Henrichs KL, et al. Der Einfluß von Nifedipin im Vergleich zu Isosorbiddinitrat und Nitroglyzerin auf die Ischämietoleranz des Herzens während perkutaner transluminaler koronarer Angioplastie: In: Meyer J, Erbel R, eds.Intravenöse und intrakoronare anwendung von adalat. Berlin: Springer-Verlag, 1985:94–104.
Pop G, Serruys PW, Piscione F, et al. Regional cardioprotection by subselective intracoronary nifedipine is not due to enhanced collateral flow during coronary angioplasty.Int J Cardiol 1987;15:27–41.
Henry PD, Shuchleib R, Clark RE, Perez JE. Effects of nifedipine on myocardial ischemia: Analysis of collateral flow, pulsatile heat and regional muscle shortening.Am J Cardiol 1979;44:817–824.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Amende, I., Herrmann, G., Simon, R. et al. Protective effects of pretreatment with intracoronary nifedipine on myocardial ischemia and dysfunction. Cardiovasc Drug Ther 4 (Suppl 5), 887–891 (1990). https://doi.org/10.1007/BF02018287
Issue Date:
DOI: https://doi.org/10.1007/BF02018287